US Rayos approval good news for Skyepharma says analyst

- Last updated on GMT

Related tags: Rheumatoid arthritis

Skyepharma, Horizon, Rayos,
Reformulation and delivery tech firm SkyPharma is set for an earnings boost following US approval for rheumatoid arthritis (RA) drug developed by Horizon Pharma.

Rayos – known as Lodotra in Europe​ where it has been approved since 2009 – is a 'circadian cytokine modulator' that mediates its therapeutic benefits through the glucocorticoid prednisone, the release of which is controlled using SkyPharma’s Geoclock technology.

In a note to investors Singer Capital Markets analyst Shawn Manning predicted that the drug could generate annual sales in the US of $50m in the next five years, 3 per cent of which would go to SkyePharma as a royalty payment.

SkyePharma is also set to earn production fees for Rayos, which will made at the facility in Lyon, France that the firm leased to German contract manufacturing group Aenova in August 2011​.

The US approval comes just weeks after European regulators approved flutiform – an asthma treatment that uses SkyPharma’s SkyeDry delivery technology that the firm is developing in Europe with Mundipharma International.

Related topics: Drug Delivery, Delivery technologies

Related news

Related products

show more

A Better Approach, for Better Pain Trials

A Better Approach, for Better Pain Trials

Signant Health | 27-Sep-2021 | Technical / White Paper

Pain studies face unique challenges. For one, pain severity can only be truly assessed by the patients themselves. The controlled substances that are often...

Related suppliers

Follow us


View more